

Anika Wranke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6062559/publications.pdf>

Version: 2024-02-01

11
papers

417
citations

1040056

9
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

558
citing authors

#	ARTICLE	IF	CITATIONS
1	Tenâ€year followâ€up of a randomized controlled clinical trial in chronic hepatitis delta. Journal of Viral Hepatitis, 2020, 27, 1359-1368.	2.0	47
2	Soluble immune markers in the different phases of chronic hepatitis B virus infection. Scientific Reports, 2019, 9, 14118.	3.3	14
3	Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers. European Journal of Gastroenterology and Hepatology, 2019, 31, 1049-1056.	1.6	7
4	Doseâ€dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis. Liver International, 2018, 38, 1602-1613.	3.9	33
5	Clinical and virological heterogeneity of hepatitis delta in different regions worldâ€wide: The Hepatitis Delta International Network (<scp>HDIN</scp>). Liver International, 2018, 38, 842-850.	3.9	72
6	Reply to Letter to the Editor. Current Opinion in Virology, 2017, 23, 131.	5.4	0
7	The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virusâ€Specific T Cells. Journal of Infectious Diseases, 2017, 215, 139-149.	4.0	32
8	Antiviral treatment and liverâ€related complications in hepatitis delta. Hepatology, 2017, 65, 414-425.	7.3	88
9	Nonâ€invasive fibrosis score for hepatitis delta. Liver International, 2017, 37, 196-204.	3.9	42
10	Antiviral therapy of hepatitis delta virus infection â€” progress and challenges towards cure. Current Opinion in Virology, 2016, 20, 112-118.	5.4	32
11	Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta. PLoS ONE, 2014, 9, e101002.	2.5	50